Losartan Potassium Tablet, Film Coated
Product Images NDC 68788-4091

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68788-4091). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartan Potassium Tab Usp 25mg (Losartan 25mg 90s Cntr)

Losartan Potassium Tab USP 25 mg film-coated tablet label by Preferred Pharmaceuticals, Inc. The label states the generic for Cozaar, each tablet containing 25 mg losartan potassium. Manufacturer is MSN Laboratories Pvt. Ltd. It includes dosing instructions for taking the tablets once daily and warnings about storage and prescription use. The label also features barcodes, and prescription directions in English and Spanish.*

FDA Label Image

Fig-1 (Losartan Fig 1)

A line graph comparing the percentage of patients with a primary endpoint over study months for Losartan potassium and Atenolol. The graph shows two lines: a solid line for Losartan potassium and a dotted line for Atenolol, with an adjusted risk reduction of 13% (p=0.021) noted on the chart.*

FDA Label Image

Fig-2 (Losartan Fig 2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over a 66-month study period between two groups treated with Atenolol and Losartan Potassium. The graph shows lower stroke incidence for Losartan Potassium with an adjusted risk reduction of 25% (p=0.001).*

FDA Label Image

Fig-3 (Losartan Fig 3)

A forest plot chart comparing Losartan potassium and Atenolol across patient demographics and clinical conditions. It displays Hazard Ratios (with 95% confidence intervals) for primary composite events and stroke outcomes, segmented by age, gender, race, isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease (CVD). The chart includes event rates and number of patients for each subgroup.*

FDA Label Image

Fig-4 (Losartan Fig 4)

A line plot comparing the percentage of patients with an event over months (up to 48) for Losartan Potassium versus placebo. The graph shows a risk reduction of 16.1% with a p-value of 0.022 for Losartan Potassium relative to placebo.*

FDA Label Image

Str (Losartan Structure)

Chemical structure diagram of losartan potassium, an oral film-coated tablet active ingredient. The structure includes potassium ion and the molecular components of losartan, such as chlorinated rings and tetrazole group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.